PAM
AVDL

PVG Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

PVG Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,040
Closed -$358K – 49
2024
Q4 		$358K Buy
+34,040
New +$413K 1.69% 26

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PVG Asset Management's AVDL Position: Q1 2025 in Review

PVG Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 34,040 shares — an estimated $358K sold.

PVG Asset Management first reported a position in AVDL in Q4 2024 and held it in 1 quarter. The position peaked at $358K in Q4 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • PVG Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • PVG Asset Management sold 34,040 Avadel Pharmaceuticals shares in Q1 2025, an estimated $358K.
  • PVG Asset Management first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • PVG Asset Management's Avadel Pharmaceuticals position peaked at $358K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on PVG Asset Management's 13F filing for Q1 2025, filed 4 Jun 2025.